Vesicare solifenacin succinate: Post-marketing study data

In the double-blind, placebo-controlled VENUS study in 739 patients, Vesicare met the primary endpoint of significant reduction in

Read the full 180 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE